Long-Acting HIV Injections Reduce Therapy Failure Risk

A new long-acting injectable therapy combining cabotegravir and rilpivirine significantly reduces the risk of treatment failure in people living with HIV who experience challenges adhering to daily medication regimens, according to results from an open-label randomized study published in the New England Journal of Medicine (DOI: 10.1056/NEJMoa2508228). This offers a potentially transformative option for individuals who struggle with consistent oral medication intake, a common barrier to effective HIV management.

Monthly intramuscular injections of the integrase inhibitor cabotegravir and the non-nucleoside reverse transcriptase inhibitor rilpivirine effectively suppress HIV viral replication. The combination received approval from regulatory agencies in the United States and Europe in 2021, initially requiring an oral lead-in phase with tablets. Though, this requirement was later removed within the same year, streamlining access to the injectable treatment.

rme